Clinical Trials Logo
  1. Home
  2. Drug Interaction Potentiation
  3. NCT03706222
  4. Details
NCT03706222 Clinical Trial

Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan

Drug Interaction Potentiation Clinical Trial

Official title:
The Real World Analysis of Drug-Drug Interactions of Grazoprevir/Elbasvir in Treatment of Chronic Hepatitis C Patients in Taiwan

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03706222
Other study ID # MISP#57751
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 22, 2018
Est. completion date February 25, 2019

Study information
Verified date March 2019
Source National Cheng-Kung University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Co-morbid diseases often present in a substantial proportion of patients with chronic hepatitis C (CHC) and require drugs to treat and control. Grazoprevir/elbavir is metabolized by cytochrome P-450 enzyme of liver. Drug-drug interactions (DDIs) are important issue before commencing direct acting antiviral agents (DAA) treatment for CHC patients. Few studies from Western countries reported that the percentages of DDIs of grazoprevir/elbasvir are limited.In Asia, real-world analysis of DDIs of grazoprevir/elbasvir is lacking and needs to be clarified.

Description:

This is a multi-center, retrospective study. Five hospitals in Taiwan and 400 patients Patients treated with grazoprevir/elbasvir during August 2017 to July 2018 are candidates of study subjects. All the required study information will be recorded with detailed chart review.

DDI will be evaluated by HEP Drug Interactions (www.hep-druginteractions.org) assessment of comidications: Category 0: Classification not possible due to lack of information; Category 1: No clinical interaction possible; Category 2: May require dose adjustment/closer monitoring; Category 3: Coadministration not recommended or contraindicated.

The assessment of DDI will be evaluated and recorded according to the suggested categories, the number of patients at risk for a clinically relevant DDI, and the ratio of patients with at least one predicted DDI between medication of grazoprevir/elbasvir will be calculated.

Recruitment information / eligibility
Status Completed
Enrollment 400
Est. completion date February 25, 2019
Est. primary completion date February 25, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Patients treated with grazoprevir/elbasvir are candidates of study subjects.

Exclusion Criteria:

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• elbasvir/grazoprevir
Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.

Locations
Country Name City State
Taiwan National Cheng Kung University Hospital Tainan

Sponsors (2)
Lead Sponsor Collaborator
National Cheng-Kung University Hospital Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

Taiwan, 

Outcome
Type Measure Description Time frame Safety issue
Primary the potential drug drug interaction of elbasvir/grazoprevor the ratio of patients with at least one predicted DDI will be analyzed. DDI will be assessed before and through the 12 weeks or 16 weeks of elbasvir/grazoprevir treatment
Secondary the comorbid diseases of CHC patients in Taiwan Comorbid diseases will be recorded and categorized by involved organ systems before elbasvir/grazoprevir treatment. Comorbid diseases will be assessed before elbasvir/grazoprevir treatment.
See also
  Status Clinical Trial Phase
Completed NCT03789032 - Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat Phase 1
Completed NCT02191358 - YouScript IMPACT Registry N/A
Completed NCT02485028 - Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg Phase 1
Completed NCT01896557 - Ranitidin Versus Omeprazole in Patients Taking Clopidogrel Phase 4
Completed NCT03011463 - Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1 Phase 1
Completed NCT02485041 - Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg Phase 1
Completed NCT01477411 - A Drug-Drug Interaction Study of Digoxin and PA21 Phase 1
Completed NCT01477424 - A Drug-Drug Interaction Study of Warfarin and PA21 Phase 1
Completed NCT05558150 - Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac Phase 1
Completed NCT03493698 - A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects Phase 1
Completed NCT03126578 - Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam Phase 1
Completed NCT01369186 - Drug Drug Interactions of Aspirin and P2Y12-inhibitors Phase 4
Completed NCT02378220 - Pharmacogenetic Testing Among Home Health Patients N/A
Completed NCT01324752 - A Drug-Drug Interaction Study of Losartan and PA21 Phase 1
Completed NCT02500667 - A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects Phase 1
Completed NCT03801733 - Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin Phase 1
Completed NCT03801759 - Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide Phase 1
Completed NCT03801746 - Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin Phase 1
Completed NCT01736371 - Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion. N/A
Completed NCT05237297 - Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole Phase 1